DB05863ExperimentalProtein Based Therapies
TRX1 is a humanized antibody that binds to the CD4 receptor found on a subset of T cells. TRX1 is being developed for the potential treatment of autoimmune diseases in... TolerRx is currently conducting a Phase I clinical study of TRX1 in the United Kingdom.
- Mechanism
- Curator reviewed
TRX1 induces and maintains immunological tolerance and reprogram the immune system to treat patients with immune-related diseases. In preclinical studies, TRX1 therapy has been shown to induce long-term, antigen-specific tolerance without compromising normal immune function.
- Primary indication
- Investigated for use/treatment in autoimmune diseases.Curator reviewed
Which companies are running trials of TRX1, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account